NCT06309355CompletedPhase 2
Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis
A Randomized, Placebo-controlled, Double-blind, Multi Center, Phase IIa Trial Investigating the Safety, Tolerability, Pharmacokinetics and Efficacy of Topical Ointment YR001 in Adult Patients With Mild to Moderate Atopic Dermatitis
Source: ClinicalTrials.gov · Last updated 18 Dec 2025
Brief summary (registry, in English)
This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in adult patients with mild to moderate atopic dermatitis
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- First submitted
- 6 Mar 2024
- Start date
- 19 Jun 2024
- Primary completion date
- 20 Nov 2025
- Lead sponsor
- Hangzhou Yirui Pharmaceutical Technology Co., Ltd
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT06309355
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 35
- From 19 Jun 2024 to the primary completion date, 20 Nov 2025
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have concomitant skin disease or infection (e.g., acne, impetigo) or presence of skin comorbidities in the skin areas to be dosed that may interfere with study assessments and treatment response.
- Participation in another interventional clinical trial (e.g. investigational drug, biological agent, or device) within 30 days or 5 half-lives of investigational agent (whichever is longer) before entering, or during the trial, or previous participation in this clinical trial.
Other
- Pregnant or lactating women.
- Any skin tattoo, scar, cuts, bruises, or other skin damage, including excessive UV exposure, at the possible IP application sites.
- Patients who have a source of itch solely or significantly from untreatable areas (face, scalp, genitals, palms of hands or soles of feet).
Who the study is looking for
- Written informed consent obtained from the subject.
- Male or female subject is aged 18 or older.
- Subject has a weight of at least 50 kg and a body mass index (BMI) between 18.0 and 30.0 kg/m2, inclusive.
- An Investigator Static Global Assessment (ISGA) score of 2 (mild) to 3 (moderate) at screening and Baseline.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| DelRicht Research Coordinator of this site? Confirm its status | Baton Rouge | United States | Unknown status |
| Encore Medical Research Boynton Beach Coordinator of this site? Confirm its status | Boynton Beach | United States | Unknown status |
| Encore Medical Research-Hollywood Coordinator of this site? Confirm its status | Hollywood | United States | Unknown status |
| Encore Medical Research - Weston Coordinator of this site? Confirm its status | Weston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.